{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:37:55Z","timestamp":1793968675517,"version":"4.8.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.neuropharm.2022.109348","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T02:02:57Z","timestamp":1668996177000},"page":"109348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system"],"prefix":"10.1016","volume":"223","author":[{"given":"Shigeyuki","family":"Chaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109348_bib1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib3","series-title":"Pharmacokinetic and Pharmacodynamic Properties of the Investigational AMPA Receptor Positive Allosteric Modulator TAK-653 after Single and Multiple Rising Doses in Healthy Volunteers","first-page":"M148","author":"Asgharnejad","year":"2018"},{"key":"10.1016\/j.neuropharm.2022.109348_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jad.2022.01.104","article-title":"mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression","volume":"303","author":"Averill","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109348_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","article-title":"Characterization of the safety and pharmacokinetic profile of d-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies","volume":"39","author":"Bernstein","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.863959","article-title":"REL-1017 (Esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats","volume":"13","author":"Bifari","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/jpet.117.242784","volume":"363","author":"Bristow","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109348_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyac043","article-title":"Zelquistinel is an orally bioavailable novel NMDA receptor allosteric modulator that exhibits rapid and sustained antidepressant-like effects","author":"Burgdorf","year":"2022","journal-title":"Int. J. Neuropsychopharmacol. pyac043."},{"key":"10.1016\/j.neuropharm.2022.109348_bib10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/1570159X15666170221101054","article-title":"Beyond ketamine: new approaches to the development of safer antidepressants","volume":"15","author":"Chaki","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tips.2017.03.008","article-title":"mGlu2\/3 receptor antagonists as novel antidepressants","volume":"38","author":"Chaki","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109348_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib13","series-title":"The Neuroscience of Depression","first-page":"381","article-title":"(2R,6R)-hydroxynorketamine as a novel antidepressant and its role in the antidepressant actions of (R,S)-ketamine","author":"Chaki","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109348_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fnbeh.2015.00162","article-title":"AMPA receptor-mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: insertion of AMPA receptor may play a role","volume":"9","author":"Chen","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109348_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2016.06.004","article-title":"Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress","volume":"316","author":"Chen","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109348_bib16","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/s41386-019-0480-y","article-title":"Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study","volume":"44","author":"Chen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.115.11.1025","article-title":"Cyloserine as an antidepressant agent","volume":"115","author":"Crane","year":"1959","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.653026","article-title":"Relationship of brain glutamate response to D-cycloserine and lurasidone to antidepressant response in bipolar depression: a pilot study","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","article-title":"REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial","volume":"179","author":"Fava","year":"2022","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib20","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-019-0501-x","article-title":"N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects","volume":"44","author":"Foga\u00e7a","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109348_bib22","series-title":"Efficacy and Safety of MIJ821 in Patients with Treatment-Resistant Depression: Results from a Randomized, Placebo-Controlled, Proof-Of-Concept Study","first-page":"P10","author":"Ghaemi","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109348_bib23","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI130808","article-title":"GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions","volume":"130","author":"Gerhard","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109348_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/JCP.0000000000001583","article-title":"REL-1017 (Esmethadone) may rapidly reduce dissociative symptoms in adults with major depressive disorder unresponsive to standard antidepressants: a report of 2 cases","volume":"42","author":"Guidetti","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1037\/pha0000310","article-title":"The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats","volume":"28","author":"Hanania","year":"2020","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109348_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173289","article-title":"TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats","volume":"211","author":"Hara","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109348_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15055-3","article-title":"REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats","volume":"12","author":"Henningfield","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109348_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","article-title":"A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression","volume":"16","author":"Heresco-Levy","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressant","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib31","doi-asserted-by":"crossref","first-page":"109272","DOI":"10.1016\/j.neuropharm.2022.109272","article-title":"Depression and antidepressant effects of ketamine and its metabolites: the pivotal role of gut microbiota","volume":"220","author":"Hua","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib32","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","article-title":"Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression","volume":"74","author":"Huang","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib34","doi-asserted-by":"crossref","first-page":"21m14345","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI)","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/biomedicines10020398","article-title":"Drug design targeting the muscarinic receptors and the implications in central nervous system disorders","volume":"10","author":"Johnson","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuropharm.2022.109348_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2005.02.032","article-title":"AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist","volume":"1042","author":"Karasawa","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109348_bib37","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI126859","article-title":"Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation","volume":"129","author":"Kato","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109348_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172827","article-title":"Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms","volume":"188","author":"Kato","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109348_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ajp.2020.20020134","article-title":"Understanding the clinical effects and mechanisms of action of neurosteroids","volume":"178","author":"Kleinman","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(02)01338-9","article-title":"Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model","volume":"440","author":"Knapp","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib41","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.neuropharm.2011.08.034","article-title":"Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists","volume":"61","author":"Koike","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib42","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine","volume":"56","author":"Kristensen","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.109348_bib43","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib44","first-page":"53","article-title":"Treatment resistant depression with loss of antidepressant response: rapid-acting antidepressant action of dextromethorphan, a possible treatment bridging molecule","volume":"46","author":"Lauterbach","year":"2016","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2022.109348_bib45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109348_bib46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109348_bib47","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib48","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Antidepressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40263-021-00877-y","article-title":"Molecular mechanisms of psilocybin and implications for the treatment of depression","volume":"36","author":"Ling","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2022.109348_bib50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00213-014-3690-3","article-title":"7-Chlorokynurenic acid (7-CTKA) produces rapid antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB-ERK\/Akt signaling pathways in mice exposed to chronic unpredictable mild stress","volume":"232","author":"Liu","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109348_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib52","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.neuropharm.2005.06.006","article-title":"GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator","volume":"49","author":"Moskal","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib53","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41386-020-00917-z","article-title":"A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans","volume":"46","author":"Murphy","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jad.2017.04.072","article-title":"Dextromethorphan\/quinidine pharmacotherapy in patients with treatment resistant depression: a proof of concept clinical trial","volume":"218","author":"Murrough","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109348_bib55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1126\/science.1329206","article-title":"Molecular diversity of glutamate receptors and implications for brain function","volume":"258","author":"Nakanishi","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109348_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2015.03.024","article-title":"Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice","volume":"295","author":"Nguyen","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109348_bib57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41398-021-01451-2","article-title":"Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation","volume":"11","author":"O'Donnell","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109348_bib58","series-title":"AXS-05 for Neuropsychiatric Disorders: Scientific Rationale and Clinical Development","first-page":"T16","author":"O'Gorman","year":"2018"},{"key":"10.1016\/j.neuropharm.2022.109348_bib59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ijnp\/pyaa025","article-title":"A randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression","volume":"23","author":"Park","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/acs.molpharmaceut.0c00727","article-title":"Probenecid increases the concentration of 7-chlorokynurenic acid derived from the prodrug 4-chlorokynurenine within the prefrontal cortex","volume":"18","author":"Patel","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neuropharm.2022.109348_bib61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1196\/annals.1300.016","article-title":"Glutamate and depression: clinical and preclinical studies","volume":"1003","author":"Paul","year":"2003","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.neuropharm.2022.109348_bib62","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17460441.2022.2111415","article-title":"Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2\/3 receptor antagonism","volume":"17","author":"Pilc","year":"2022","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2022.109348_bib63","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1038\/s41380-020-0796-3","article-title":"Cell-type specific modulation of NMDA receptors triggers antidepressant actions","volume":"26","author":"Pothula","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib64","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41386-020-00882-7","article-title":"Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons","volume":"46","author":"Pothula","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib65","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/01.pra.0000462606.17725.93","article-title":"Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent","volume":"21","author":"Preskorn","year":"2015","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.neuropharm.2022.109348_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16060-7","article-title":"Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model","volume":"7","author":"Qu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109348_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109348_bib69","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib70","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1038\/s41598-019-40693-5","article-title":"Discovery of NV-5138, the first selective Brain mTORC1 activator","volume":"9","author":"Sengupta","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109348_bib71","first-page":"20","volume":"vol. 684","author":"Sheffler","year":"2019"},{"key":"10.1016\/j.neuropharm.2022.109348_bib72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","article-title":"Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine","volume":"21","author":"Shirayama","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","article-title":"Glutamate-based antidepressants: 20 years on","volume":"30","author":"Skolnick","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109348_bib74","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1017\/S1092852919001470","article-title":"Dextromethorphan\/Bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity","volume":"24","author":"Stahl","year":"2019","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pbb.2019.06.004","article-title":"TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats","volume":"183","author":"Suzuki","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109348_bib76","article-title":"Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant","author":"Suzuki","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib77","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant action","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib79","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12470","article-title":"Randomized, double-blind, placebo-controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81","author":"Umbricht","year":"2020","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ijnp\/pyab062","article-title":"Evaluation of the safety, tolerability, and pharmacokinetic profiles of TP0473292 (TS-161), a prodrug of a novel orthosteric mGlu2\/3 receptor antagonist TP0178894, in healthy subjects and its antidepressant-like effects in rodents","volume":"25","author":"Watanabe","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172854","article-title":"mGlu2\/3 receptor antagonism: a mechanism to induce rapid antidepressant effects without ketamine-associated side-effects","volume":"190","author":"Witkin","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109348_bib83","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/187152707780363302","article-title":"Metabotropic glutamate receptors in the control of mood disorders","volume":"6","author":"Witkin","year":"2007","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.neuropharm.2022.109348_bib84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.apha.2020.03.003","article-title":"Involvement of muscarinic receptor mechanisms in antidepressant drug action","volume":"89","author":"Witkin","year":"2020","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109348_bib85","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","article-title":"(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice","volume":"43","author":"Yamaguchi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib86","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00213-016-4399-2","article-title":"Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression","volume":"233","author":"Yang","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109348_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109348_bib88","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib89","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41398-017-0031-4","article-title":"Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"7","author":"Yang","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109348_bib90","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.biopsych.2018.05.007","article-title":"AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine","volume":"84","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib91","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib92","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172876","article-title":"(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression","volume":"191","author":"Yokoyama","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109348_bib94","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.115.225664","article-title":"The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA\/GlycineB-Site inhibition","volume":"355","author":"Zanos","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109348_bib95","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109348_bib96","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2022.109348_bib97","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109348_bib98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109348_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109348_bib100","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00213-018-5017-2","article-title":"Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109348_bib101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109348_bib102","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1503\/jpn.120228","article-title":"Glycine site N-methyl-D-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats","volume":"38","author":"Zhu","year":"2013","journal-title":"J. Psychiatry Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822004075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822004075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:22:30Z","timestamp":1758439350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822004075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":102,"alternative-id":["S0028390822004075"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109348","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109348"}}